JP2015520759A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520759A5
JP2015520759A5 JP2015512967A JP2015512967A JP2015520759A5 JP 2015520759 A5 JP2015520759 A5 JP 2015520759A5 JP 2015512967 A JP2015512967 A JP 2015512967A JP 2015512967 A JP2015512967 A JP 2015512967A JP 2015520759 A5 JP2015520759 A5 JP 2015520759A5
Authority
JP
Japan
Prior art keywords
metformin
composition
metazolamide
combination
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015512967A
Other languages
English (en)
Japanese (ja)
Other versions
JP6438389B2 (ja
JP2015520759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/000259 external-priority patent/WO2013173858A1/en
Publication of JP2015520759A publication Critical patent/JP2015520759A/ja
Publication of JP2015520759A5 publication Critical patent/JP2015520759A5/ja
Application granted granted Critical
Publication of JP6438389B2 publication Critical patent/JP6438389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015512967A 2012-05-24 2013-03-15 減量法 Expired - Fee Related JP6438389B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
PCT/AU2013/000259 WO2013173858A1 (en) 2012-05-24 2013-03-15 A method of weight reduction

Publications (3)

Publication Number Publication Date
JP2015520759A JP2015520759A (ja) 2015-07-23
JP2015520759A5 true JP2015520759A5 (https=) 2016-05-12
JP6438389B2 JP6438389B2 (ja) 2018-12-12

Family

ID=49622926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512967A Expired - Fee Related JP6438389B2 (ja) 2012-05-24 2013-03-15 減量法

Country Status (16)

Country Link
US (2) US20150174108A1 (https=)
EP (1) EP2854806A4 (https=)
JP (1) JP6438389B2 (https=)
KR (1) KR20150023404A (https=)
CN (1) CN104582701B (https=)
AU (1) AU2013202981B2 (https=)
BR (1) BR112014029302A2 (https=)
CA (1) CA2874512A1 (https=)
CO (1) CO7160083A2 (https=)
HK (1) HK1209041A1 (https=)
MX (1) MX2014014316A (https=)
NZ (1) NZ702666A (https=)
RU (1) RU2664442C2 (https=)
SG (1) SG11201407786XA (https=)
WO (1) WO2013173858A1 (https=)
ZA (1) ZA201408703B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
CA2419158A1 (en) * 2000-08-11 2002-02-21 Einar Stefansson Method for the prevention and treatment of retinopathy
JP2006520335A (ja) * 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
EP1617832B1 (en) * 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EA010422B1 (ru) 2003-08-01 2008-08-29 Янссен Фармацевтика Н.В. Замещённые индол-о-глюкозиды
WO2007114948A2 (en) * 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
TW201105338A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Medicine derived from a combination of SGLT1-inhibitor and DPP-IV inhibitor
US20130143797A1 (en) * 2010-06-25 2013-06-06 Michael J. Tisdale Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof
WO2012008549A1 (ja) * 2010-07-15 2012-01-19 武田薬品工業株式会社 複素環化合物
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática

Similar Documents

Publication Publication Date Title
JP2013507415A5 (https=)
JP2015512406A5 (https=)
JP2007519649A5 (https=)
JP2014506321A5 (https=)
JP2017533972A5 (https=)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
IL314873A (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
JP2019515908A5 (https=)
JP2019515884A5 (https=)
JP2016516773A5 (https=)
JP2013532729A5 (https=)
JP2008534453A5 (https=)
JP2019533660A5 (https=)
JP2020500864A5 (https=)
JP2021512906A5 (https=)
JP2015520759A5 (https=)
JP2016505050A5 (https=)
JP2017508737A5 (https=)
JP2019507786A5 (https=)
JP2019531286A5 (https=)
JP2018525447A5 (https=)
RU2014150946A (ru) Способ снижения веса
JPWO2020080451A1 (ja) 糖尿病腎症における腎線維化抑制剤
JP6940265B2 (ja) 止瀉剤組成物
JPWO2020037152A5 (https=)